Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4545472 | 0.84 | LMNA (0.63) | GAALMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4545464 | 0.81 | LMNA (0.62) | GAALMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL86223 | 0.81 | LMNA (0.64) | GAALMNASMN1; SMN2MAOBMAOA | |
| SCHEMBL14129739 | 0.78 | LMNA (0.61) | GAALMNANPC1SMN1; SMN2MAOB | |
| SCHEMBL1772322 | 0.75 | LMNA (0.54) | GAALMNAMAPTSMN1; SMN2MAOB | |
| SCHEMBL13226830 | 0.75 | LMNA (0.60) | GAALMNANPC1MAPTRAB9A | |
| SCHEMBL20101965 | 0.74 | SMN1; SMN2 (0.43) | GAALMNANPC1MAPTXBP1 | |
| SCHEMBL23223241 | 0.73 | LMNA (0.58) | GAALMNASMN1; SMN2MAOBMAOA | |
| SCHEMBL19329810 | 0.73 | LMNA (0.58) | GAALMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21975951 | 0.72 | LMNA (0.56) | GAALMNANPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3391888-B1 | MEDICINE FOR TREATING INFLUENZA CHARACTERIZED BY COMPRISING COMBINATION OF CAP-DEPENDENT ENDONUCLEASE INHIBITOR WITH ANTI-INFLUENZA DRUG | SHIONOGI & CO (JP) | 2023-09-27 | — | — | EP | disclosed |
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-4219508-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND PRODRUG THEREOF | Shionogi & Co., Ltd (JP) | 2023-08-02 | — | — | EP | disclosed |
| EP-3290424-B1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | SHIONOGI & CO (JP) | 2023-01-04 | — | — | EP | disclosed |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | SHIONOGI & CO., LTD. (JP) | 2021-06-22 | — | — | US | disclosed |
| US-20200361958-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | SHIONOGI & CO., LTD. (JP) | 2020-11-19 | — | — | US | disclosed |
| US-20200283455-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-10759814-B2 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | SHIONOGI & CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | SHIONOGI & CO., LTD. (JP) | 2020-08-20 | — | — | US | disclosed |
| US-10633397-B2 | Substituted polycyclic pyridone derivatives and prodrugs thereof | SHIONOGI & CO., LTD. (JP) | 2020-04-28 | — | — | US | disclosed |
| US-10392406-B2 | Substituted polycyclic pyridone derivatives and prodrugs thereof | SHIONOGI & CO., LTD. (JP) | 2019-08-27 | — | — | US | disclosed |
| US-20190169206-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | SHIONOGI & CO., LTD. (JP) | 2019-06-06 | — | — | US | disclosed |
| US-10294241-B2 | — | — | 2019-05-21 | — | — | US | disclosed |
| US-20190112315-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2019-04-18 | — | — | US | disclosed |
| US-20180118760-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180118760-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361958-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | TYMP, PNP, CYP3A4 | GAA 628/4885LMNA 1759/4885NPC1 1738/4885 |
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | GAA 4535/4885LMNA 1318/4885NPC1 3542/4885 |
| US-20190169206-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | TYMP, PNP, CYP3A4 | GAA 628/4885LMNA 1759/4885NPC1 1738/4885 |
| US-10294241-B2 | — | C3AR1, HAVCR2, NR4A1 | GAA 4432/4885LMNA 2068/4885NPC1 2041/4885 |
| US-10633397-B2 | Substituted polycyclic pyridone derivatives and prodrugs thereof | C3AR1, NR4A1, HAVCR2 | GAA 4535/4885LMNA 1318/4885NPC1 3542/4885 |
| US-10392406-B2 | Substituted polycyclic pyridone derivatives and prodrugs thereof | C3AR1, NR4A1, HAVCR2 | GAA 4535/4885LMNA 1318/4885NPC1 3542/4885 |
| US-20190112315-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | GAA 4535/4885LMNA 1318/4885NPC1 3542/4885 |
| US-20200283455-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | GAA 4535/4885LMNA 1318/4885NPC1 3542/4885 |
| US-10759814-B2 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | TYMP, PNP, CYP3A4 | GAA 628/4885LMNA 1759/4885NPC1 1738/4885 |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | RNASEH1, RNASEL, RNPEP | GAA 1320/4885LMNA 1560/4885NPC1 2543/4885 |
| US-20180118760-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | GAA 4535/4885LMNA 1318/4885NPC1 3542/4885 |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | RNASEH1, RNPEP, RNASEL | GAA 1583/4885LMNA 1825/4885NPC1 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.